A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.
The bill’s titles are written by its sponsor.
Sep 9, 2015
114th Congress, 2015–2017
Died in a previous Congress
This bill was introduced on September 9, 2015, in a previous session of Congress, but was not enacted.
Senior Senator from Minnesota
Read Text »
Last Updated: Sep 9, 2015
Length: 17 pages
Earlier Version — Introduced
This activity took place on a related bill, S. 214 (113th).
This is the first step in the legislative process.
Reintroduced Bill — Introduced
This activity took place on a related bill, S. 124.
S. 2019 (114th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
Civic Impulse. (2017). S. 2019 — 114th Congress: Preserve Access to Affordable Generics Act. Retrieved from https://www.govtrack.us/congress/bills/114/s2019
“S. 2019 — 114th Congress: Preserve Access to Affordable Generics Act.” www.GovTrack.us. 2015. February 20, 2017 <https://www.govtrack.us/congress/bills/114/s2019>
|title=S. 2019 (114th)
|accessdate=February 20, 2017
|author=114th Congress (2015)
|date=September 9, 2015
|quote=Preserve Access to Affordable Generics Act
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.